New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders
WO2008103327A2
Mn/ca ix and bladder cancer
CN101679362A
4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cance
WO2008079972A2
4-{4- [ ({3-tert-butyl-1- [3- (hydroxymethyl) phenyl] - 1h- pyrazol- 5 -yl } carbamoyl) -amin o] -3-chlorophenoxy} -n-methylpyridine-2-carboxamide as an inhibitor of the vegfr kinase for the treatment of cancer
DK200700434A
Modified IL-4 mutein receptor antagonists
CA2646971A1
Paclitaxel combination
TW200804397A
Tetrahydropyridothienopyrimidine compounds and methods of use thereof
JP2007125037A
Cryopreservation bag assembly for mammalian cell lines
WO2007075650A2
Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
CN101600707A
The carbamide compound that is used for the treatment of cancer
BRPI0619146A2
Substituted 4-amino-pyrroltriazine derivatives useful in the treatment of disorders and hyperproliferative diseases associated with angiogenesis
CN101448506A
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
CA2629468A1
Pyrazolyl urea derivatives useful in the treatment of cancer
WO2007059155A1
Treatment of cancers having resistance to chemotherapeutic agents
CA2629863A1
Use of sorafenib for the treatment of cancers with acquired resistance to kit inhibitors
EP1954272A2
Treatment of cancer with sorafenib
EP1883419A2
Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006121904A1
Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
CA2607273A1
Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
